The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas.

PURPOSE The aim of the study was to determine the impact of positron emission tomography using the glucose analogue fluorine-18-fluorodeoxyglucose (FDG-PET) on the delineation of the target volume in three-dimensional radiation treatment planning of primary brain tumors. METHODS AND MATERIALS In 18 patients with histologically proven (8x biopsy, 10x subtotal resection) primary brain tumors (8 astrocytomas grade III, one mixed glioma grade III, and 9 glioblastomas), magnetic resonance imaging (MRI) with gadolinium-DTPA and FDG-PET were performed in radiation treatment position within the same week. A computer program was developed for fusion of the PET and MR images. On corresponding axial slices, FDG uptake was compared to contrast enhancement in T1-weighted and to signal hyperintensity in T2-weighted MR images. Based on PET and MRI data, three-dimensional treatment planning was performed. All patients underwent linear accelerator (LINAC) radiotherapy. RESULTS In MRI, all tumors and the surrounding edema were visible as hyperintense lesions in the T2-weighted images. 17/18 tumors showed contrast enhancement. In FDG-PET, 16 tumors showed hypermetabolism compared to normal white matter, whereas only 8/18 tumors showed hypermetabolism compared to normal gray matter. White matter edema was associated with decreased FDG uptake in all patients. The area of increased FDG uptake correlated closely with contrast enhancement, only in one case the volume of increased FDG uptake was larger than the area of contrast enhancement. Mean tumor volumes obtained by MRI T1 + Gd, T2, and PET were 30, 106, and 10 ml, respectively. Survival was comparable to data in the literature with a 1-year survival of 39% and a median survival of 310 days. CONCLUSION Only in a minority of patients did FDG-PET provide additional information for radiation treatment planning. This is mainly caused by the high intensity of FDG uptake in normal brain tissue. PET may be of greater value in the definition of regions that should obtain a radiation dose boost.

[1]  W. Paulus,et al.  Intratumoral histologic heterogeneity of gliomas. A quantitative study , 1989, Cancer.

[2]  D L McShan,et al.  The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. , 1992, International journal of radiation oncology, biology, physics.

[3]  Kiyoshi Sato,et al.  Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas , 1995, Cancer.

[4]  G. Chiro.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .

[5]  S. Goldman,et al.  Regional glucose metabolism and histopathology of gliomas: A study based on positron emission tomography‐guided stereotactic biopsy , 1996, Cancer.

[6]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[8]  J. Marks,et al.  Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. , 1981, International journal of radiation oncology, biology, physics.

[9]  U Pietrzyk,et al.  An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  S C Strother,et al.  Display of merged multimodality brain images using interleaved pixels with independent color scales. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  D. Kinzel,et al.  Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  S. Coons,et al.  Histopathology of astrocytomas: Grading, patterns of spread, and correlation with modern imaging modalities , 1991 .

[13]  K. Wallner,et al.  Patterns of second recurrence of malignant astrocytomas. , 1990, International journal of radiation oncology, biology, physics.

[14]  Abass Alavi,et al.  Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.

[15]  T. Greitz,et al.  Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. , 1981, Journal of computer assisted tomography.

[16]  R A Brooks,et al.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography , 1982, Neurology.

[17]  M. Salcman,et al.  Long-term survival in patients with malignant astrocytoma. , 1994, Neurosurgery.

[18]  R. Maciunas,et al.  Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.

[19]  W D Heiss,et al.  FDG‐PET as a Prognostic Indicator in Radiochemotherapy of Glioblastoma , 1993, Journal of computer assisted tomography.

[20]  M. Bernstein,et al.  Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. , 1992, International journal of radiation oncology, biology, physics.

[21]  C. Perez,et al.  Principles and Practice of Radiation Oncology , 1987 .

[22]  A. Friedman,et al.  Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography , 1991, Annals of neurology.

[23]  W. Olivero,et al.  The use of PET in evaluating patients with primary brain tumours: is it useful? , 1995, Journal of neurology, neurosurgery, and psychiatry.